Sollmann Lea, Eveslage Maria, Danzer Moritz Fabian, Schäfers Michael, Heitplatz Barbara, Conrad Elke, Hescheler Daniel, Riemann Burkhard, Noto Benjamin
Department of Nuclear Medicine, University of Münster and University Hospital Münster, 48149 Münster, Germany.
Institute of Biostatistics and Clinical Research, University of Münster, 48149 Münster, Germany.
Cancers (Basel). 2024 Dec 16;16(24):4184. doi: 10.3390/cancers16244184.
Thyroid nodules are common yet remain a diagnostic challenge. While ultrasound and Thyroid Imaging Reporting and Data Systems (TIRADS) are accepted as standard, the use of thyroid scintigraphy in euthyroid patients is debated. The European Association of Nuclear Medicine advocates it, whereas the American Thyroid Association and European Thyroid Association do not. However, it has not been evaluated whether scintigraphy adds value to TIRADS in a multimodal approach. Our study addresses this gap by assessing the impact of integrated pertechnetate scintigraphy on TIRADS accuracy. The diagnostic performance of ACR-TIRADS, EU-TIRADS, pertechnetate scintigraphy, and multimodal models were retrospectively analyzed for 322 nodules (231 benign, 91 malignant) in 208 euthyroid patients with histopathology as a reference. Generalized estimating equations were used for statistical analysis. On scintigraphy, 210 nodules were hypofunctional, 99 isofunctional, and 13 hyperfunctional. The AUC for thyroid scintigraphy, ACR-TIRADS, and EU-TIRADS were 0.6 (95% CI: 0.55-0.66), 0.83 (95% CI: 0.78-0.88), and 0.78 (95% CI: 0.72-0.83). Integrating scintigraphy with ACR-TIRADS and EU-TIRADS slightly increased diagnostic accuracy (AUC 0.86 vs. 0.83, = 0.039 and AUC 0.80 vs. 0.78, = 0.008) and adjusted the malignancy probability for intermediate risk TIRADS categories, with iso- or hyperfunctioning nodules in ACR-TIRADS-TR4 or EU-TIRADS-4 showing comparable malignancy probabilities as hypofunctioning nodules in TR3 or EU-TIRADS-3, respectively. Integrating thyroid scintigraphy with ACR- or EU-TIRADS moderately improves diagnostic performance, potentially benefiting management, especially in complex cases like multinodular goiter or indeterminate FNA. Further research is warranted to validate these findings and explore their clinical implications.
甲状腺结节很常见,但仍然是一个诊断难题。虽然超声和甲状腺影像报告和数据系统(TIRADS)被公认为标准方法,但甲状腺功能正常患者使用甲状腺闪烁扫描的情况仍存在争议。欧洲核医学协会提倡使用,而美国甲状腺协会和欧洲甲状腺协会则不提倡。然而,闪烁扫描在多模态方法中是否能为TIRADS增加价值尚未得到评估。我们的研究通过评估锝酸盐闪烁扫描对TIRADS准确性的影响来填补这一空白。以组织病理学为参考,对208例甲状腺功能正常患者的322个结节(231个良性,91个恶性)回顾性分析了美国放射学会(ACR)-TIRADS、欧洲(EU)-TIRADS、锝酸盐闪烁扫描及多模态模型的诊断性能。采用广义估计方程进行统计分析。在闪烁扫描中,210个结节功能减退,99个功能正常,13个功能亢进。甲状腺闪烁扫描、ACR-TIRADS和EU-TIRADS的曲线下面积(AUC)分别为0.6(95%可信区间:0.55-0.66)、0.83(95%可信区间:0.78-0.88)和0.78(95%可信区间:0.72-0.83)。将闪烁扫描与ACR-TIRADS和EU-TIRADS相结合可略微提高诊断准确性(AUC分别为0.86对0.83,P = 0.039;以及AUC为0.80对0.78,P = 0.008),并调整了TIRADS中等风险类别的恶性概率,ACR-TIRADS-TR4或EU-TIRADS-4中功能正常或亢进的结节分别显示出与TR3或EU-TIRADS-3中功能减退结节相当的恶性概率。将甲状腺闪烁扫描与ACR-TIRADS或EU-TIRADS相结合可适度提高诊断性能,可能有助于管理,尤其是在多结节性甲状腺肿或不确定细针穿刺活检等复杂病例中。有必要进行进一步研究以验证这些发现并探索其临床意义。